Psoriasis outcome measures: A report from the GRAPPA 2012 annual meeting

Journal of Rheumatology

Volumn 40, Issue 8, 2013, Pages 1428-1433

  Gottlieb, Alice B ^a   Armstrong, April W ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Comorbidities; National psoriasis foundation; OMERACT; Psoriasis; Psoriatic disease

Indexed keywords

ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; METABOLIC SYNDROME X; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SELF ESTEEM; SMOKING;

COMORBIDITIES; NATIONAL PSORIASIS FOUNDATION; OMERACT; PSORIASIS; PSORIATIC DISEASE;

COMORBIDITY; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PSORIASIS; QUALITY OF LIFE; SWEDEN;

EID: 84881458668     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130456     Document Type: Conference Paper

References (64)

1. Wan J, Abuabara K, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF Jr, et al. Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. J Am Acad Dermatol 2012;66:376-86.
2. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007;57:957-62.
3. Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: Cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004;20:1929-36.
4. Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 2011;25:157-63.
5. Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, et al. A study examining inter-and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol 2006;155:707-13.
6. Fredriksson T, Pettersson U. Severe psoriasis-Oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
7. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51:563-9.
8. Schmitt J, Wozel G. The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210:194-9.
9. Farhi D, Falissard B, Dupuy A. Global assessment of psoriasis severity and change from photographs: A valid and consistent method. J Invest Dermatol 2008;128:2198-203.
10. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991;124:565-70.
11. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-A simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
12. Rogers A, DeLong LK, Chen SC. Clinical meaning in skin-specific quality of life instruments: A comparison of the Dermatology Life Quality Index and Skindex banding systems. Dermatol Clin 2012;30:333-42.
13. Rich P, Scher RK. Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12.
14. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii65-8; discussion ii9-73.
15. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA 2003;290:3073-80.
16. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: Results from two randomized clinical trials. Health Qual Life Outcomes 2003;1:53.
17. Schleyer V, Radakovic-Fijan S, Karrer S, Zwingers T, Tanew A, Landthaler M, et al. Disappointing results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study. J Eur Acad Dermatol Venereol 2006;20:823-8.
18. Harari M, Shani J, Hristakieva E, Stanimirovic A, Seidl W, Burdo A. Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead Sea. Int J Dermatol 2000;39:913-8.
19. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: Quantitative evaluation in a systematic review. J Invest Dermatol 2010;130:933-43.
20. Louden BA, Pearce DJ, Lang W, Feldman SR. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J 2004;10:7.
21. Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: The impact of area should be increased. Br J Dermatol 2004;151:381-7.
22. Berth-Jones J, Thompson J, Papp K. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: The Copenhagen Psoriasis Severity Index. Br J Dermatol 2008;159:407-12.
23. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): A comparison. J Drugs Dermatol 2003;2:260-6.
24. Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CE. The Salford Psoriasis Index: An holistic measure of psoriasis severity. Br J Dermatol 2000;142:728-32.
25. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality. Br J Dermatol 1999;141:185-91.
26. Faust HB, Gonin R, Chuang TY, Lewis CW, Melfi CA, Farmer ER. Reliability testing of the Dermatology Index of Disease Severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol 1997;133:1443-8.
27. Williams HC. Is a simple generic index of dermatologic disease severity an attainable goal? Arch Dermatol 1997;133:1451-2.
28. Bushnell DM, Martin ML, McCarrier K, Gordon K, Chiou CF, Huang X, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat 2012 Dec 8. [Epub ahead of print]
29. Feldman SR, Clark AR, Venkat AP, Fleischer AB Jr, Anderson RT, Rajagopalan R. The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity. Br J Dermatol 2005;152:382-3.
30. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Exum ML, Clark AR, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996;106:183-6.
31. Fleischer AB Jr, Feldman SR, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol 1999;26:210-5.
32. Sampogna F, Sera F, Mazzotti E, Pasquini P, Picardi A, Abeni D. Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch Dermatol 2003;139:353-8; discussion 7.
33. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997;133:1433-40.
34. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res 2011;63 Suppl 11:S240-52.
35. Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011;38:898-903.
36. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
37. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 2011;63 Suppl 11:S64-85.
38. Ortonne JP, Shear N, Shumack S, Henninger E. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: Results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol 2005;5:13.
39. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: Results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008;158:549-57.
40. Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008;216:260-70.
41. Jemec GB, van de Kerkhof PC, Enevold A, Ganslandt C. Significant one week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation. J Eur Acad Dermatol Venereol 2011;25:27-32.
42. Toth DP, Papp K, Gratton D. Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis. Dermatol Ther 2008;21 Suppl 3:S6-14.
43. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): Initial validation and practical use. Br J Dermatol 1995;132:942-9.
44. Augustin M, Wenninger K, Amon U, Schroth MJ, Kuster W, Chren M, et al. German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: Validation and clinical results. Dermatology 2004;209:14-20.
45. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: Reliability, validity, and responsiveness. J Invest Dermatol 1996;107:707-13.
46. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 Health Survey questionnaire: New outcome measure for primary care. BMJ 1992;305:160-4.
47. Fong DY, Lam CL, Mak KK, Lo WS, Lai YK, Ho SY, et al. The Short Form-12 Health Survey was a valid instrument in Chinese adolescents. J Clin Epidemiol 2010;63:1020-9.
48. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33.
49. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis. Br J Dermatol 1990;123:751-6.
50. Nichol MB, Margolies JE, Lippa E, Rowe M, Quell J. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996; 10:644-53.
51. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales-A measure of the impact of skin diseases. Br J Dermatol 1997;136:202-6.
52. Augustin M, Zschocke I, Seidenglanz K, Lange S, Schiffler A, Amon U. Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin disease. Dermatol Psychosom 2000;01:12-7.
53. de Bruin AF, Buys M, de Witte LP, Diederiks JP. The sickness impact profile: SIP68, a short generic version. First evaluation of the reliability and reproducibility. J Clin Epidemiol 1994; 47:863-71.
54. de Bruin AF, Diederiks JP, de Witte LP, Stevens FC, Philipsen H. The development of a short generic version of the Sickness Impact Profile. J Clin Epidemiol 1994;47:407-18.
55. Moorey S, Greer S, Watson M, Gorman C, Rowden L, Tunmore R, et al. The factor structure and factor stability of the Hospital Anxiety and Depression Scale in patients with cancer. Br J Psychiatry 1991;158:255-9.
56. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-70.
57. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess 1996;67:588-97.
58. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
59. Lipps GE, Lowe GA, De La Haye W, Longman-Mills S, Clarke TR, Barton EN, et al. Validation of the Beck Depression Inventory II in HIV-positive patients. West Indian Med J 2010;59:374-9.
60. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65.
61. Lerner D, Amick BC 3rd, Rogers WH, Malspeis S, Bungay K, Cynn D. The Work Limitations Questionnaire. Med Care 2001;39:72-85.
62. Lerner D, Reed JI, Massarotti E, Wester LM, Burke TA. The Work Limitations Questionnaire's validity and reliability among patients with osteoarthritis. J Clin Epidemiol 2002;55:197-208.
63. Koo J, Kozma C, Reinke K. The development of a disease-specific questionnaire to assess quality of life for psoriasis patients: An analysis of the reliability, validity, and responsiveness of the Psoriasis Quality of Life Questionnaire. Dermatol Psychosom 2002;3:171-9.
64. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25:198-9.